Want to join the conversation?
$JNJ subsidiary, Janssen Research, said The FDA has granted a fourth Breakthrough Therapy Designation for IMBRUVICA for treating patients with chronic graft-versus-host-disease (cGVHD). FDA also granted the therapy Orphan Drug Designation for cGVHD. IMBRUVICA is jointly developed and commercialized by Janssen Biotech and Pharmacyclics.
$EXTR has been on an interesting uptrend, fundamentals kinda tricky but solid technical. Earnings 5th
Wow! $MCD scores again.